Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

3d ago, source:

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...

Zimberelimab by Arcus Biosciences for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

10d ago, source: Pharmaceutical Technology

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)

15d ago, source:

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bausch Health Companies (BHC – Research Report) and Arcus ...

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

11d ago, source:

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three ...

Precision BioSciences (DTIL) Price Target Decreased by 22.17% to 36.52

11d ago, source: Fintel on MSN

The average one-year price target for Precision BioSciences (NasdaqCM:DTIL) has been revised to 36.52 / share. This is an ...

Buy Rating Affirmed for Precision BioSciences Amid Strong Gene Editing Prospects and Upcoming Milestones

10d ago, source:

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Precision BioSciences (DTIL – Research Report), with ...

Arcadia Biosciences (RKDA) Announces Date of First Quarter 2024 Financial Results and Business Highlights Conference Call

2d ago, source: Joplin Globe

Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for ...

Should You Invest in Coherus Biosciences Inc (CHRS) Now?

2d ago, source: newsheater

In conclusion, Coherus Biosciences Inc (CHRS) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important ...

LIVE UPDATES: Day 3 of Harvard Yard Encampment

1d ago, source: The Harvard Crimson

The encampment in Harvard Yard mounted by pro-Palestine student organizers entered its second day on Friday. Students are ...

Entrepreneurs Earn Green at Clean Green Challenge

10d ago, source: UMass Lowell

By Ed Brennen A line of zero-waste home cleaning products and technology to turn sewage and toxic “forever chemicals” into ...

A clinical decision support system for Earth-independent medical operations

on MSN ago, source:

Deep space exploration requires a paradigm shift in astronaut medical support toward Earth-independent medical operations.

Caribou Biosciences Inc (CRBU) Shares Plummet Below 1-Year High

4mon ago, source: newsheater

Based on Caribou Biosciences Inc (CRBU), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -3.39. The debt to equity ratio ...